Ajax Therapeutics
Onco
Daily
Facebook
RSS
X
Youtube
Linkedin
October, 2024
October 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Sep
Ajax Therapeutics
May 15, 2024, 12:01 |
Blog
David Steensma: IND application for first type II JAK2 inhibitor to go into clinical trials
David Steensma, Chief Medical Officer at Ajax Therapeutics, shared a post by Ajax Therapeutics on X/Twitter:…
May 14, 2024, 15:32 |
Blog
Big Day for Ajax Therapeutics with 2 big announcements
Ajax Therapeutics shared on X/Twitter: "Big Day for Ajax Therapeutics with 2 big announcements! Number 1:…
Dec 23, 2023, 03:29 |
Blog
David Steensma: The NIH modular R01's direct cost cap of $250K is unchanged since 1998
David Steensma, Chief Medical Officer at Ajax Therapeutics, recently posted on X/Twitter: "The NIH modular…
Nov 20, 2023, 04:08 |
Insight
Adam C Palmer: You don’t need ‘1+1 makes 3’ if you can have ‘5+5 makes 10’
David Steensma, Chief Medical Officer at Ajax Therapeutics, and Anthony Letai, Professor at Dana-Farber Cancer…
All:
4
Posts:
1 - 100
ASTRO24: 15 Posts Not To Miss From Day 4
Top 100 Xfluencers in Prostate Cancer: Key Opinion Leaders to follow on X (Twitter) in 2024
Paper Alert! Cutaneous Metastases in Thyroid Cancer: A Comprehensive Review of 136 Cases
ASTRO 24: 15 Posts Not to Miss From Day 3
Gavin Creel: Broadway Icon Dies After Battle with Rare Sarcoma at 48
Special Coverage
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Facebook
RSS Feed
X
Linkedin
Youtube